A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1
Authors
Keywords
-
Journal
PLoS One
Volume 8, Issue 10, Pages e76280
Publisher
Public Library of Science (PLoS)
Online
2013-10-12
DOI
10.1371/journal.pone.0076280
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lack of GPR40/FFAR1does not induce diabetes even under insulin resistance condition
- (2013) K. Matsuda-Nagasumi et al. DIABETES OBESITY & METABOLISM
- Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1
- (2013) Yumei Xiong et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes
- (2012) E Leifke et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Optimization of (2,3-Dihydro-1-benzofuran-3-yl)acetic Acids: Discovery of a Non-Free Fatty Acid-Like, Highly Bioavailable G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist as a Glucose-Dependent Insulinotropic Agent
- (2012) Nobuyuki Negoro et al. JOURNAL OF MEDICINAL CHEMISTRY
- TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial
- (2012) Charles F Burant et al. LANCET
- A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents
- (2012) Jian Luo et al. PLoS One
- GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes
- (2011) T. Araki et al. DIABETES OBESITY & METABOLISM
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK-875: Results From a Double-Blind, Placebo-Controlled Single Oral Dose Rising Study in Healthy Volunteers
- (2011) Himanshu Naik et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists
- (2011) Shinobu Sasaki et al. JOURNAL OF MEDICINAL CHEMISTRY
- AMG 837: A Novel GPR40/FFA1 Agonist that Enhances Insulin Secretion and Lowers Glucose Levels in Rodents
- (2011) Daniel C.-H. Lin et al. PLoS One
- Molecular docking and molecular dynamics simulation studies of GPR40 receptor–agonist interactions
- (2010) Shao-Yong Lu et al. JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist
- (2010) Nobuyuki Negoro et al. ACS Medicinal Chemistry Letters
- Fatty acids and β-cell toxicity
- (2009) Noel G Morgan CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- Deletion of GPR40 Impairs Glucose-Induced Insulin Secretion In Vivo in Mice Without Affecting Intracellular Fuel Metabolism in Islets
- (2009) T. Alquier et al. DIABETES
- Overexpression of GPR40 in Pancreatic -Cells Augments Glucose-Stimulated Insulin Secretion and Improves Glucose Tolerance in Normal and Diabetic Mice
- (2009) K. Nagasumi et al. DIABETES
- Selective Small-Molecule Agonists of G Protein-Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice
- (2008) C. P. Tan et al. DIABETES
- Lack of FFAR1/GPR40 Does Not Protect Mice From High-Fat Diet-Induced Metabolic Disease
- (2008) H. Lan et al. DIABETES
- Gpr40 Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin Secretion
- (2008) S. Edfalk et al. DIABETES
- Two Arginine-Glutamate Ionic Locks Near the Extracellular Surface of FFAR1 Gate Receptor Activation
- (2008) Chi Shing Sum et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of Potent and Selective Agonists for the Free Fatty Acid Receptor 1 (FFA1/GPR40), a Potential Target for the Treatment of Type II Diabetes
- (2008) Elisabeth Christiansen et al. JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search